PDB Short entry for 1GZQ HEADER GLYCOPROTEIN 24-MAY-02 1GZQ TITLE CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL COMPND MOL_ID: 1; COMPND 2 MOLECULE: T-CELL SURFACE GLYCOPROTEIN CD1B; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 18-295; COMPND 5 SYNONYM: CD1B ANTIGEN; COMPND 6 ENGINEERED: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: B2-MICROGLOBULIN; COMPND 9 CHAIN: B; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PROKARYOTIC EXPRESSION SYSTEM; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET23D; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 17 EXPRESSION_SYSTEM_VECTOR: PROKARYOTIC EXPRESSION SYSTEM; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET23D KEYWDS PHOPHATIDYLINOSITOL, MHC, GLYCOPROTEIN, ANTIGEN PRESENTATION EXPDTA X-RAY DIFFRACTION AUTHOR S.D.GADOLA,N.R.ZACCAI,K.HARLOS,D.SHEPHERD,G.RITTER,R.R.SCHMIDT, AUTHOR 2 E.Y.JONES,V.CERUNDOLO REVDAT 4 08-MAY-19 1GZQ 1 REMARK REVDAT 3 09-AUG-17 1GZQ 1 SOURCE REMARK REVDAT 2 24-FEB-09 1GZQ 1 VERSN REVDAT 1 31-JUL-02 1GZQ 0 JRNL AUTH S.D.GADOLA,N.R.ZACCAI,K.HARLOS,D.SHEPHERD, JRNL AUTH 2 J.C.CASTRO-PALOMINO,G.RITTER,R.R.SCHMIDT,E.Y.JONES, JRNL AUTH 3 V.CERUNDOLO JRNL TITL STRUCTURE OF HUMAN CD1B WITH BOUND LIGANDS AT 2.3 A, A MAZE JRNL TITL 2 FOR ALKYL CHAINS JRNL REF NAT.IMMUNOL. V. 3 721 2002 JRNL REFN ISSN 1529-2908 JRNL PMID 12118248 JRNL DOI 10.1038/NI821 REMARK 2 REMARK 2 RESOLUTION. 2.26 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.26 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 24.30 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 1307389.190 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 91.1 REMARK 3 NUMBER OF REFLECTIONS : 25407 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.203 REMARK 3 FREE R VALUE : 0.237 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.000 REMARK 3 FREE R VALUE TEST SET COUNT : 751 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.26 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.40 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 72.30 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 3220 REMARK 3 BIN R VALUE (WORKING SET) : 0.3140 REMARK 3 BIN FREE R VALUE : 0.3860 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 3.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 100 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.039 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2997 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 102 REMARK 3 SOLVENT ATOMS : 196 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 36.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 58.70 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 14.73000 REMARK 3 B22 (A**2) : -10.81000 REMARK 3 B33 (A**2) : -3.92000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.29 REMARK 3 ESD FROM SIGMAA (A) : 0.35 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.38 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.45 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.90 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.860 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 2.560 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 3.910 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 4.570 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 6.060 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.32 REMARK 3 BSOL : 41.49 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : LIPID2_11.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER.TOP REMARK 3 TOPOLOGY FILE 3 : GM2_11.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1GZQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 24-MAY-02. REMARK 100 THE DEPOSITION ID IS D_1290009899. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-OCT-01 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.10 REMARK 200 NUMBER OF CRYSTALS USED : 2 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID29 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 334867 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -0.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 92.3 REMARK 200 DATA REDUNDANCY : 12.10 REMARK 200 R MERGE (I) : 0.05100 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 39.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.28 REMARK 200 COMPLETENESS FOR SHELL (%) : 89.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.20600 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 15.80 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PARTIALLY REFINED STRUCTURE OF CD1B-GM2 COMPLEX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 64.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.25 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20 DEGREES C, 2UL OF PROTEIN + 1UL OF REMARK 280 MOTHER LIQUOR, 0.2M LITHIUM NITRATE, 20% W/V POLYETHYLENE GLYCOL REMARK 280 3350, PH 7.1, PH 7.10, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 37.63850 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 37.63850 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 43.94050 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 88.49900 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 43.94050 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 88.49900 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 37.63850 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 43.94050 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 88.49900 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 37.63850 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 43.94050 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 88.49900 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -2 REMARK 465 GLY A -1 REMARK 465 SER A 0 REMARK 465 GLU A 1 REMARK 465 HIS A 2 REMARK 465 SER A 281 REMARK 465 GLY A 282 REMARK 465 GLY A 283 REMARK 465 GLY A 284 REMARK 465 LEU A 285 REMARK 465 ASN A 286 REMARK 465 ASP A 287 REMARK 465 ILE A 288 REMARK 465 PHE A 289 REMARK 465 GLU A 290 REMARK 465 ALA A 291 REMARK 465 GLN A 292 REMARK 465 LYS A 293 REMARK 465 ILE A 294 REMARK 465 GLU A 295 REMARK 465 TRP A 296 REMARK 465 HIS A 297 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A 280 CA C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -119.93 61.48 REMARK 500 GLN A 89 74.18 48.01 REMARK 500 PHE A 123 -43.11 -131.64 REMARK 500 ASN A 128 65.31 30.17 REMARK 500 ALA A 129 18.15 57.05 REMARK 500 GLU A 164 -50.20 -121.49 REMARK 500 ALA A 239 -6.58 -59.61 REMARK 500 PRO A 279 -174.79 -59.67 REMARK 500 ASN B 21 -151.35 -135.96 REMARK 500 LYS B 75 -143.38 -106.93 REMARK 500 ASP B 76 99.82 65.28 REMARK 500 VAL B 85 -17.45 -48.93 REMARK 500 REMARK 500 REMARK: NULL REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NO3 A1281 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NO3 A1282 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NO3 A1283 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PII A1280 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE D12 A1284 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TWT A1285 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1GZP RELATED DB: PDB REMARK 900 CD1B IN COMPLEX WITH GM2 GANGLIOSIDE REMARK 900 RELATED ID: 1A1M RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDETYPDINQML FROM REMARK 900 GAG PROTEIN OF HIV2 REMARK 900 RELATED ID: 1A1N RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTYFROM THE REMARK 900 NEF PROTEIN (75- 82) OF HIV1 REMARK 900 RELATED ID: 1A1O RELATED DB: PDB REMARK 900 MHC CLASS I MOLECULE B5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) REMARK 900 FROM THE MALARIA PARASITE P. FALCIPARUM REMARK 900 RELATED ID: 1A6Z RELATED DB: PDB REMARK 900 HFE (HUMAN) HEMOCHROMATOSIS PROTEIN REMARK 900 RELATED ID: 1A9B RELATED DB: PDB REMARK 900 DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE REMARK 900 TO NONSTANDARD POSITIONING OF THE C-TERMINUS REMARK 900 RELATED ID: 1A9E RELATED DB: PDB REMARK 900 DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE REMARK 900 TO NONSTANDARD POSITIONING OF THE C-TERMINUS REMARK 900 RELATED ID: 1AGB RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGRKKYKL - 3R MUTATION) REMARK 900 RELATED ID: 1AGC RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYQL - 7Q MUTATION) REMARK 900 RELATED ID: 1AGD RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYKL - INDEX PEPTIDE) REMARK 900 RELATED ID: 1AGE RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKKYRL - 7R MUTATION) REMARK 900 RELATED ID: 1AGF RELATED DB: PDB REMARK 900 ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - REMARK 900 HIV-1 GAG PEPTIDE (GGKKRYKL - 5R MUTATION) REMARK 900 RELATED ID: 1AKJ RELATED DB: PDB REMARK 900 COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 ANDTHE T CELL REMARK 900 CORECEPTOR CD8 REMARK 900 RELATED ID: 1CE6 RELATED DB: PDB REMARK 900 MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUSNUCLEOPROTEIN PEPTIDE REMARK 900 RELATED ID: 1DE4 RELATED DB: PDB REMARK 900 HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRINRECEPTOR REMARK 900 RELATED ID: 1E27 RELATED DB: PDB REMARK 900 NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV REMARK 900 IMMUNODOMINANT EPITOPE KM1 (LPPVVAKEI) REMARK 900 RELATED ID: 1E28 RELATED DB: PDB REMARK 900 NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV REMARK 900 IMMUNODOMINANT EPITOPE KM2 (TAFTIPSI) REMARK 900 RELATED ID: 1EFX RELATED DB: PDB REMARK 900 STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL REMARK 900 RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3 REMARK 900 RELATED ID: 1EXU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR REMARK 900 RELATED ID: 1HHG RELATED DB: PDB REMARK 900 RELATED ID: 1HHH RELATED DB: PDB REMARK 900 RELATED ID: 1HHI RELATED DB: PDB REMARK 900 RELATED ID: 1HHJ RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEX WITH REMARK 900 A NONAMERIC PEPTIDE FROM HIV-1 REVERSE TRANSCRIPTASE (RESIDUES 309- REMARK 900 317) REMARK 900 RELATED ID: 1HHK RELATED DB: PDB REMARK 900 RELATED ID: 1HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2 ( HLA-A2, HUMAN REMARK 900 LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 1HSA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA- B(ASTERISK)2705 REMARK 900 RELATED ID: 1HSB RELATED DB: PDB REMARK 900 CLASS I HISTOCOMPATIBILITY ANTIGEN AW68.1 ( LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 1I4F RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4- PEPTIDE COMPLEX REMARK 900 RELATED ID: 1I7R RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1058 REMARK 900 RELATED ID: 1I7T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-5V REMARK 900 RELATED ID: 1I7U RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-6V REMARK 900 RELATED ID: 1IM3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2BOUND TO REMARK 900 THE MHC CLASS I MOLECULE HLA-A2/TAX REMARK 900 RELATED ID: 1IM9 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELLINHIBITORY REMARK 900 RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4 REMARK 900 RELATED ID: 1JF1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ADECAMERIC ALTERED REMARK 900 PEPTIDE LIGAND FROM THE MART-1/MELAN-A REMARK 900 RELATED ID: 1JHT RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ANONAMERIC ALTERED REMARK 900 PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A. REMARK 900 RELATED ID: 1JNJ RELATED DB: PDB REMARK 900 NMR SOLUTION STRUCTURE OF THE HUMAN BETA2- MICROGLOBULIN REMARK 900 RELATED ID: 1QLF RELATED DB: PDB REMARK 900 MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G REMARK 900 RELATED ID: 1QQD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER REMARK 900 CELL INHIBITORY RECEPTOR REMARK 900 RELATED ID: 1TMC RELATED DB: PDB REMARK 900 TRUNCATED HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA-AW68 REMARK 900 COMPLEXED WITH A DECAMERIC PEPTIDE (EVAPPEYHRK) REMARK 900 RELATED ID: 2CLR RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEXED REMARK 900 WITH A DECAMERIC PEPTIDE FROM CALRETICULIN REMARK 900 RELATED ID: 2HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN AW 68.1 (HLA-AW 68.1, REMARK 900 HUMAN LEUCOCYTE ANTIGEN) REMARK 900 RELATED ID: 3HLA RELATED DB: PDB REMARK 900 HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2. 1 (HLA-A2.1 HUMAN REMARK 900 LEUCOCYTE ANTIGEN) REMARK 999 REMARK 999 SEQUENCE REMARK 999 RESIDUES GLYCINE A278 AND PROLINE A279 ARE THE STARTING REMARK 999 RESIDUES OF A BIRA TAG (GPGSGGGLNDIFEAQKIEWH) WHICH WAS REMARK 999 LOCATED AT THE C-TERMINUS OF THE RECOMBINANT CD1B REMARK 999 HEAVY CHAIN. DBREF 1GZQ A -2 -1 PDB 1GZQ 1GZQ -2 -1 DBREF 1GZQ A 0 277 UNP P29016 CD1B_HUMAN 18 295 DBREF 1GZQ A 278 297 PDB 1GZQ 1GZQ 278 297 DBREF 1GZQ B 0 0 PDB 1GZQ 1GZQ 0 0 DBREF 1GZQ B 1 99 UNP P01884 B2MG_HUMAN 21 119 SEQRES 1 A 300 MET GLY SER GLU HIS ALA PHE GLN GLY PRO THR SER PHE SEQRES 2 A 300 HIS VAL ILE GLN THR SER SER PHE THR ASN SER THR TRP SEQRES 3 A 300 ALA GLN THR GLN GLY SER GLY TRP LEU ASP ASP LEU GLN SEQRES 4 A 300 ILE HIS GLY TRP ASP SER ASP SER GLY THR ALA ILE PHE SEQRES 5 A 300 LEU LYS PRO TRP SER LYS GLY ASN PHE SER ASP LYS GLU SEQRES 6 A 300 VAL ALA GLU LEU GLU GLU ILE PHE ARG VAL TYR ILE PHE SEQRES 7 A 300 GLY PHE ALA ARG GLU VAL GLN ASP PHE ALA GLY ASP PHE SEQRES 8 A 300 GLN MET LYS TYR PRO PHE GLU ILE GLN GLY ILE ALA GLY SEQRES 9 A 300 CYS GLU LEU HIS SER GLY GLY ALA ILE VAL SER PHE LEU SEQRES 10 A 300 ARG GLY ALA LEU GLY GLY LEU ASP PHE LEU SER VAL LYS SEQRES 11 A 300 ASN ALA SER CYS VAL PRO SER PRO GLU GLY GLY SER ARG SEQRES 12 A 300 ALA GLN LYS PHE CYS ALA LEU ILE ILE GLN TYR GLN GLY SEQRES 13 A 300 ILE MET GLU THR VAL ARG ILE LEU LEU TYR GLU THR CYS SEQRES 14 A 300 PRO ARG TYR LEU LEU GLY VAL LEU ASN ALA GLY LYS ALA SEQRES 15 A 300 ASP LEU GLN ARG GLN VAL LYS PRO GLU ALA TRP LEU SER SEQRES 16 A 300 SER GLY PRO SER PRO GLY PRO GLY ARG LEU GLN LEU VAL SEQRES 17 A 300 CYS HIS VAL SER GLY PHE TYR PRO LYS PRO VAL TRP VAL SEQRES 18 A 300 MET TRP MET ARG GLY GLU GLN GLU GLN GLN GLY THR GLN SEQRES 19 A 300 LEU GLY ASP ILE LEU PRO ASN ALA ASN TRP THR TRP TYR SEQRES 20 A 300 LEU ARG ALA THR LEU ASP VAL ALA ASP GLY GLU ALA ALA SEQRES 21 A 300 GLY LEU SER CYS ARG VAL LYS HIS SER SER LEU GLU GLY SEQRES 22 A 300 GLN ASP ILE ILE LEU TYR TRP GLY PRO GLY SER GLY GLY SEQRES 23 A 300 GLY LEU ASN ASP ILE PHE GLU ALA GLN LYS ILE GLU TRP SEQRES 24 A 300 HIS SEQRES 1 B 100 MET ILE GLN ARG THR PRO LYS ILE GLN VAL TYR SER ARG SEQRES 2 B 100 HIS PRO ALA GLU ASN GLY LYS SER ASN PHE LEU ASN CYS SEQRES 3 B 100 TYR VAL SER GLY PHE HIS PRO SER ASP ILE GLU VAL ASP SEQRES 4 B 100 LEU LEU LYS ASN GLY GLU ARG ILE GLU LYS VAL GLU HIS SEQRES 5 B 100 SER ASP LEU SER PHE SER LYS ASP TRP SER PHE TYR LEU SEQRES 6 B 100 LEU TYR TYR THR GLU PHE THR PRO THR GLU LYS ASP GLU SEQRES 7 B 100 TYR ALA CYS ARG VAL ASN HIS VAL THR LEU SER GLN PRO SEQRES 8 B 100 LYS ILE VAL LYS TRP ASP ARG ASP MET HET PII A1280 56 HET NO3 A1281 4 HET NO3 A1282 4 HET NO3 A1283 4 HET D12 A1284 12 HET TWT A1285 22 HETNAM PII 2-[(HYDROXY{[(2R,3R,5S,6R)-2,3,4,5,6- HETNAM 2 PII PENTAHYDROXYCYCLOHEXYL]OXY}PHOSPHORYL)OXY]-1- HETNAM 3 PII [(PALMITOYLOXY)METHYL]ETHYL HEPTADECANOATE HETNAM NO3 NITRATE ION HETNAM D12 DODECANE HETNAM TWT DOCOSANE FORMUL 3 PII C42 H81 O13 P FORMUL 4 NO3 3(N O3 1-) FORMUL 7 D12 C12 H26 FORMUL 8 TWT C22 H46 FORMUL 9 HOH *196(H2 O) HELIX 1 1 SER A 59 ALA A 85 1 27 HELIX 2 2 GLY A 137 ILE A 149 1 13 HELIX 3 3 TYR A 151 GLU A 164 1 14 HELIX 4 4 GLU A 164 GLY A 177 1 14 HELIX 5 5 GLY A 177 GLN A 182 1 6 HELIX 6 6 GLY A 254 ALA A 256 5 3 HELIX 7 7 HIS A 265 GLU A 269 5 5 SHEET 1 AA 8 THR A 46 PHE A 49 0 SHEET 2 AA 8 LEU A 35 ASP A 41 -1 O GLY A 39 N ILE A 48 SHEET 3 AA 8 TRP A 23 LEU A 32 -1 O GLY A 28 N TRP A 40 SHEET 4 AA 8 SER A 9 ASN A 20 -1 O HIS A 11 N TRP A 31 SHEET 5 AA 8 PHE A 94 LEU A 104 -1 O PHE A 94 N PHE A 18 SHEET 6 AA 8 ILE A 110 LEU A 118 -1 O VAL A 111 N GLU A 103 SHEET 7 AA 8 LEU A 121 LYS A 127 -1 O LEU A 121 N LEU A 118 SHEET 8 AA 8 SER A 130 PRO A 133 -1 O SER A 130 N LYS A 127 SHEET 1 AB 4 GLU A 188 SER A 193 0 SHEET 2 AB 4 ARG A 201 PHE A 211 -1 O VAL A 205 N SER A 192 SHEET 3 AB 4 THR A 242 ALA A 252 -1 O TRP A 243 N GLY A 210 SHEET 4 AB 4 GLN A 231 LEU A 232 -1 O GLN A 231 N THR A 248 SHEET 1 AC 4 GLU A 188 SER A 193 0 SHEET 2 AC 4 ARG A 201 PHE A 211 -1 O VAL A 205 N SER A 192 SHEET 3 AC 4 THR A 242 ALA A 252 -1 O TRP A 243 N GLY A 210 SHEET 4 AC 4 LEU A 236 ASN A 238 -1 O LEU A 236 N TYR A 244 SHEET 1 AD 4 GLN A 225 GLU A 226 0 SHEET 2 AD 4 TRP A 217 ARG A 222 -1 O ARG A 222 N GLN A 225 SHEET 3 AD 4 LEU A 259 LYS A 264 -1 O SER A 260 N MET A 221 SHEET 4 AD 4 ILE A 273 TYR A 276 -1 O ILE A 273 N VAL A 263 SHEET 1 BA 4 LYS B 6 SER B 11 0 SHEET 2 BA 4 ASN B 21 PHE B 30 -1 O ASN B 24 N TYR B 10 SHEET 3 BA 4 PHE B 62 PHE B 70 -1 O PHE B 62 N PHE B 30 SHEET 4 BA 4 GLU B 50 HIS B 51 -1 O GLU B 50 N TYR B 67 SHEET 1 BB 4 LYS B 6 SER B 11 0 SHEET 2 BB 4 ASN B 21 PHE B 30 -1 O ASN B 24 N TYR B 10 SHEET 3 BB 4 PHE B 62 PHE B 70 -1 O PHE B 62 N PHE B 30 SHEET 4 BB 4 SER B 55 PHE B 56 -1 O SER B 55 N TYR B 63 SHEET 1 BC 4 GLU B 44 ARG B 45 0 SHEET 2 BC 4 GLU B 36 LYS B 41 -1 O LYS B 41 N GLU B 44 SHEET 3 BC 4 TYR B 78 ASN B 83 -1 O ALA B 79 N LEU B 40 SHEET 4 BC 4 LYS B 91 LYS B 94 -1 O LYS B 91 N VAL B 82 SSBOND 1 CYS A 102 CYS A 166 1555 1555 2.05 SSBOND 2 CYS A 131 CYS A 145 1555 1555 2.04 SSBOND 3 CYS A 206 CYS A 261 1555 1555 2.02 SSBOND 4 CYS B 25 CYS B 80 1555 1555 2.03 CISPEP 1 TYR A 92 PRO A 93 0 -0.18 CISPEP 2 TYR A 212 PRO A 213 0 0.27 CISPEP 3 HIS B 31 PRO B 32 0 0.06 SITE 1 AC1 7 PRO A 7 TYR A 212 PRO A 213 LYS A 214 SITE 2 AC1 7 PRO A 215 TRP A 243 HOH A2027 SITE 1 AC2 4 GLY A 233 ASP A 234 ARG A 246 GLN B 8 SITE 1 AC3 3 LEU A 161 THR A 165 PII A1280 SITE 1 AC4 14 ILE A 69 VAL A 72 TYR A 73 ALA A 100 SITE 2 AC4 14 VAL A 126 ALA A 129 CYS A 131 GLY A 153 SITE 3 AC4 14 MET A 155 THR A 157 ILE A 160 LEU A 161 SITE 4 AC4 14 NO3 A1283 TWT A1285 SITE 1 AC5 6 GLU A 80 PHE A 84 MET A 90 PHE A 144 SITE 2 AC5 6 TYR A 151 TWT A1285 SITE 1 AC6 7 VAL A 12 GLN A 14 TRP A 40 PHE A 70 SITE 2 AC6 7 PHE A 123 PII A1280 D12 A1284 CRYST1 87.881 176.998 75.277 90.00 90.00 90.00 C 2 2 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011379 0.000000 0.000000 0.00000 SCALE2 0.000000 0.005650 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013284 0.00000